Skip to content

Using artificial intelligence to study the law of cancer symptoms can help more accurate diagnosis and individualized treatment

Using artificial intelligence to study the law of cancer symptoms can help more accurate diagnosis and individualized treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001939
Enrollment
Unknown
Registered
2025-10-15
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

breast cancer:N/A
ovarian cancer:N/A

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-75 years; (2) Patients with breast cancer and epithelial ovarian cancer with definite pathological or histological diagnosis; (3) patients with breast cancer undergoing perioperative and postoperative adjuvant chemotherapy and hormone receptor-positive endocrine therapy in stage I-IIIA, Postoperative chemotherapy patients with ovarian cancer; (4) ECOG-PS 0-1; (5) Have a certain understanding and expression ability, voluntarily participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system; (2) pregnant women, breast-feeding, mental illness, mental and language disorders, and other mental disorders (such as strong) Obsessive-compulsive disorder, personality disorder, schizophrenia, bipolar disorder, etc.); (3) Patients with primary tumors in other parts; (4) Participate in other clinical trials within 3 months;

Design outcomes

Primary

MeasureTime frame
symptom cluster;

Secondary

MeasureTime frame
Evaluation index of tumor curative effect (progressive disease stable disease partial response complete response);Survival evaluation data (Overall Survival Progression-Free Survival Disease-Free Survival etc.);

Countries

China

Contacts

Public ContactYingyi WANG

Peking Union Medical College Hospital

wangyingyi@pumch.cn13241016888

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026